Quantcast

Industry news that matters to you.  Learn more

Archives for October 2011

Vermillion Announces Positive Top-Line Data from Intended Use Study for Peripheral Artery Disease (PAD)

Vermillion, Inc., a molecular diagnostics company, today announced positive top-line results from the intended use study for its peripheral artery disease (PAD) blood test, VASCLIR. The goals of the study were to validate the markers described in earlier publications (Circulation, 2007 and Vascular Medicine, 2008) and to develop and validate a biomarker panel applicable to the intended use population.

Generation Scotland, Arrayjet Partner to Develop New Products and Services for Biomarker Identification and Development.

Generation Scotland (GS) and Arrayjet Ltd are pleased to announce a new collaboration. The project builds on the complementary strengths of Generation Scotland and Arrayjet; combining high quality research, human biobank material and health data with cutting edge inkjet microarray technology.

Biomarker for Huntington’s Disease Identified

Huntington’s disease, a devastating genetic disorder that causes degeneration of nerve cells in the brain, affects more than 15,000 Americans, and at least 150,000 are at risk of developing the disease. There is no known cure or treatment for the disease — which starts with changes in mood, judgment, memory, and other cognitive functions and inevitably leads to increasing physical disability, dementia and death. In a new research paper published in the Proceedings of the National Academy of Sciences Early Edition online, researchers identify a transcriptional biomarker that may assist in the monitoring of disease activity and in the evaluation of new medications.

United States Drug Testing Laboratories Unveils New Alcohol Biomarker in Umbilical Cord

United States Drug Testing Laboratories (USDTL), a reference laboratory specializing in alcohol and drugs of abuse testing, today released a new assay testing umbilical cord for newborn alcohol exposure in utero. The CordStat EtOH assay screens for the direct alcohol biomarker phosphatidylethanol (PEth), an abnormal phospholipid formed in cell tissues following alcohol ingestion.

Lupus Experts Gather at the FDA to Explore Potential for Biomarkers to Accelerate Clinical Trials

Biomarkers, potential indicators to monitor disease progress and treatment success, are among the most challenging and critical areas of lupus research according representatives of industry, academia, government and advocacy attending a U.S. Food and Drug Administration workshop this week. The meeting was convened to focus on the development of biomarkers to predict acute worsening of disease, called a flare, and their potential for accelerating lupus clinical trials and new drug approvals.